Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 13 | 2024 | 286 | 3.880 |
Why?
|
| Lung Neoplasms | 12 | 2024 | 2360 | 1.680 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2024 | 1124 | 1.610 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2024 | 111 | 1.120 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 755 | 1.090 |
Why?
|
| Oropharyngeal Neoplasms | 6 | 2024 | 132 | 0.990 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 65 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 2503 | 0.860 |
Why?
|
| Trachea | 1 | 2024 | 292 | 0.850 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 1096 | 0.820 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.810 |
Why?
|
| Tongue Neoplasms | 1 | 2022 | 52 | 0.780 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.730 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 63 | 0.720 |
Why?
|
| Pneumonia | 1 | 2022 | 183 | 0.720 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1395 | 0.710 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 1059 | 0.710 |
Why?
|
| Mouth Neoplasms | 1 | 2022 | 199 | 0.680 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1703 | 0.630 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2018 | 15 | 0.610 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 399 | 0.600 |
Why?
|
| Immunotherapy | 5 | 2024 | 693 | 0.590 |
Why?
|
| Radiotherapy | 3 | 2024 | 332 | 0.580 |
Why?
|
| Papillomavirus Infections | 4 | 2024 | 264 | 0.510 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 598 | 0.500 |
Why?
|
| Carcinoma | 3 | 2024 | 437 | 0.490 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 305 | 0.470 |
Why?
|
| Humans | 41 | 2025 | 90014 | 0.470 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2317 | 0.450 |
Why?
|
| Esophagectomy | 1 | 2014 | 91 | 0.430 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 1998 | 0.420 |
Why?
|
| Anastomosis, Surgical | 1 | 2014 | 277 | 0.410 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 782 | 0.410 |
Why?
|
| Prospective Studies | 5 | 2024 | 4326 | 0.400 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 331 | 0.380 |
Why?
|
| Radiation Injuries | 4 | 2024 | 160 | 0.360 |
Why?
|
| Carboplatin | 4 | 2024 | 311 | 0.360 |
Why?
|
| Retrospective Studies | 14 | 2024 | 9239 | 0.340 |
Why?
|
| Aged | 18 | 2024 | 19269 | 0.330 |
Why?
|
| Middle Aged | 20 | 2024 | 26179 | 0.320 |
Why?
|
| Survival Rate | 5 | 2024 | 1898 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1350 | 0.290 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6784 | 0.290 |
Why?
|
| Female | 21 | 2024 | 46620 | 0.280 |
Why?
|
| Male | 19 | 2024 | 42705 | 0.280 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3682 | 0.260 |
Why?
|
| Sarcoma | 2 | 2018 | 219 | 0.260 |
Why?
|
| Adult | 15 | 2024 | 26845 | 0.260 |
Why?
|
| Ipilimumab | 2 | 2022 | 60 | 0.250 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2018 | 173 | 0.240 |
Why?
|
| Organ Sparing Treatments | 1 | 2024 | 46 | 0.230 |
Why?
|
| Thoracic Neoplasms | 1 | 2024 | 66 | 0.230 |
Why?
|
| Papillomaviridae | 2 | 2022 | 156 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 167 | 0.230 |
Why?
|
| Etoposide | 1 | 2024 | 205 | 0.220 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 165 | 0.220 |
Why?
|
| Neoplasms | 3 | 2024 | 3065 | 0.220 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 152 | 0.210 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 80 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.200 |
Why?
|
| Tongue | 1 | 2022 | 57 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 374 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 3021 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 263 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.180 |
Why?
|
| Lymph Nodes | 2 | 2022 | 550 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.180 |
Why?
|
| Prognosis | 5 | 2022 | 3794 | 0.170 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1543 | 0.170 |
Why?
|
| Tissue Expansion | 1 | 2019 | 20 | 0.170 |
Why?
|
| Breast Implantation | 1 | 2019 | 14 | 0.160 |
Why?
|
| Breast Implants | 1 | 2019 | 26 | 0.160 |
Why?
|
| Xerostomia | 1 | 2018 | 10 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 230 | 0.160 |
Why?
|
| Submandibular Gland | 1 | 2018 | 17 | 0.160 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 49 | 0.160 |
Why?
|
| Osteonecrosis | 1 | 2018 | 22 | 0.150 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 49 | 0.150 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 606 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2022 | 8295 | 0.140 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 40 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 247 | 0.140 |
Why?
|
| Paclitaxel | 3 | 2024 | 474 | 0.140 |
Why?
|
| Necrosis | 1 | 2017 | 210 | 0.140 |
Why?
|
| Brachytherapy | 1 | 2017 | 120 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 853 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 265 | 0.120 |
Why?
|
| Esophagitis | 1 | 2015 | 43 | 0.120 |
Why?
|
| Esophageal Stenosis | 1 | 2015 | 26 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 333 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 523 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 82 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2024 | 2886 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1681 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2328 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2024 | 584 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1746 | 0.080 |
Why?
|
| Brain | 1 | 2017 | 2310 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 1065 | 0.070 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 468 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 185 | 0.070 |
Why?
|
| Education, Medical, Continuing | 1 | 2025 | 106 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2024 | 42 | 0.060 |
Why?
|
| Young Adult | 3 | 2022 | 6423 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 127 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 280 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 263 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 152 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 548 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2020 | 278 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 598 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 784 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 475 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 101 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 172 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1055 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2019 | 110 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 872 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 39 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 9352 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 278 | 0.040 |
Why?
|
| Mastectomy | 1 | 2019 | 246 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3189 | 0.030 |
Why?
|
| United States | 2 | 2022 | 7115 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 605 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 846 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 301 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 290 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1227 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 809 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 960 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 368 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1496 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 846 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 412 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1468 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 682 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 591 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1604 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5362 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 5566 | 0.020 |
Why?
|